A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Arvinas Estrogen Receptor, Inc..
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Other
Enrollment
10actual
Sites
2
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-03 | actual | When the study began enrolling |
| Primary completion | 2025-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-13 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Vepdegestrant (Reference) — also filed as ARV-471, PF-07850327
- Drug: Vepdegestrant (Test) — also filed as ARV-471, PF-07850327
Primary outcomes
what the primary-completion date above is the date OFDose-normalized (dn) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant after oral administration
measured At predefined intervals throughout the treatment period, up to approximately 1 week after the last dose of Vepdegestrant
Dose-normalized (dn) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant after IV administration
measured At predefined intervals throughout the treatment period, up to approximately 1 week after the last dose of Vepdegestrant
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed